Home
Categories
EXPLORE
True Crime
Comedy
Business
Society & Culture
Sports
History
News
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/11/80/1c/11801cfd-09ae-4247-00ce-e0cac30af906/mza_16016720903821846029.jpg/600x600bb.jpg
Board Agenda: The Macro Memo
Questor Media
26 episodes
4 weeks ago
In this episode of Macro Memo, we unpack the big forces shaping business as we head into 2026. From the looming U.S. Supreme Court decision on trade tariffs, to the reality behind AI adoption, and the EU’s major revisions to sustainability reporting, our experts Mark Kennedy and George Lagarias from Forvis Mazars, join host Gavin Hinks to explore what these shifts mean for companies worldwide—and what leaders should watch in the year ahead.
Show more...
Management
Business,
Careers
RSS
All content for Board Agenda: The Macro Memo is the property of Questor Media and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode of Macro Memo, we unpack the big forces shaping business as we head into 2026. From the looming U.S. Supreme Court decision on trade tariffs, to the reality behind AI adoption, and the EU’s major revisions to sustainability reporting, our experts Mark Kennedy and George Lagarias from Forvis Mazars, join host Gavin Hinks to explore what these shifts mean for companies worldwide—and what leaders should watch in the year ahead.
Show more...
Management
Business,
Careers
https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/11/80/1c/11801cfd-09ae-4247-00ce-e0cac30af906/mza_16016720903821846029.jpg/600x600bb.jpg
What’s next for boards in the UK pharma and life sciences industry? Navigating the challenges of innovation, productivity and ESG in a post Covid world.
Board Agenda: The Macro Memo
44 minutes
2 years ago
What’s next for boards in the UK pharma and life sciences industry? Navigating the challenges of innovation, productivity and ESG in a post Covid world.
What’s next for boards in the UK pharma and life sciences industry? Navigating the challenges of innovation, productivity and ESG in a post Covid world. The life science industry is in a dynamic phase of transformation which has been rapidly accelerated by the pandemic, with more workforce agility, shortening development and review times, increased speed to market, and greater efficiencies. In response to the pandemic, life sciences companies mobilized impressively to meet the needs of...
Board Agenda: The Macro Memo
In this episode of Macro Memo, we unpack the big forces shaping business as we head into 2026. From the looming U.S. Supreme Court decision on trade tariffs, to the reality behind AI adoption, and the EU’s major revisions to sustainability reporting, our experts Mark Kennedy and George Lagarias from Forvis Mazars, join host Gavin Hinks to explore what these shifts mean for companies worldwide—and what leaders should watch in the year ahead.